2021-06-01
Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treated with both doses of investigational risankizumab (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo (p<0.001 for each) in two Phase 3 induction studies.
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal (or digestive) tract, causing persistent diarrhea, abdominal pain, and rectal bleeding. It is a progressive disease, meaning it gets worse over time. Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically, but also emotionally and economically.During the 12-week induction period, the safety profile of risankizumab in both studies was generally consistent with the known safety profile of risankizumab from previous clinical trials. No new safety risks were observed.